Mass spectrometry, a powerful tool for studying tiny molecules, has long helped scientists unlock secrets hidden in plants, ...

Researchers led by Université de Montréal pathology and cell-biology professor Marc Therrien have identified major structural ...

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide ...

Terns Pharmaceuticals, Inc. ("Terns” or the "Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing ...

SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

National Institute of Health (NIH) scientists report that a first-in-human clinical trial of a new therapy based on the plant ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end BGE-102 induced weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

Presenting Author: MRK Alley, Ph.D. A copy of the poster will be available on the AN2 Therapeutics website at the following link simultaneously with the poster session Development Pipeline | AN2 ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...